When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…
In this expert interview, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses donor selection for allogeneic stem cell transplantation in secondary acute myeloid leukemia (AML) patients…
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a study evaluating the efficacy of combining venetoclax with hypomethylating agents in treating patients with acute myeloid leukemia…
Stephen Strickland, MD, Sarah Cannon Research Institute, AML patient and neurologist Dr Joseph, and patient advocate Steve Buechler discuss the critical role of molecular and genetic testing in…
Richard Gale, MBChB, PhD, professor of ophthalmology, Hull York Medical School, UK, presents long-term real-world outcomes of intravitreal aflibercept 8 mg in patients with diabetic macular edema. Over…
Kelvin Teo, MBBS, PhD, senior consultant, Advanced Eye Clinic & Surgery, adjunct associate professor, Duke NUS Eye ACP, Singapore, presents real-world data showing that a single 8-mg dose…
Andrew Chang, MBBS, PhD, consultant ophthalmologist and head of Ophthalmology, Sydney Eye Hospital, Australia, shares real-world experience using 8-mg intravitreal aflibercept for neovascular age-related macular degeneration and reports…
Profiling the metabolites produced by cells in Richter transformation could help researchers develop new targeted therapies in the future. Dr. Prajish Iyer from City of Hope National Comprehensive…
Fatima Tuz Zahra, MD, a hematology/oncology fellow at Moffitt Cancer Center, University of South Florida, Tampa, presented real-world data from a retrospective study evaluating the effectiveness of oral…
In this episode of The AML Expert Series, Amer Zeidan, MBBS, Yale School of Medicine, New Haven, Connecticut, and Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center,…
